Clinical short communication| Volume 367, P15-17, August 15, 2016

Propranolol stops progressive multiple cerebral cavernoma in an adult patient


      • There is no proven treatment for adults with CCM and recurrent hemorrhages so far.
      • This case and two other recent cases suggest a beneficial effect of propranolol.
      • Future clinical studies should evaluate propranolol as treatment for aggressive CCM.



      To report a case of a patient with multiple cerebral cavernous malformations (CCM).


      A 22 year old man with mild von Willebrand disease presented with two occipital CCM, one of them with acute hemorrhage. Genetic testing for CCM1–3 did not reveal a mutation. Over a period of 54 months, the patient suffered 26 new CCM hemorrhages despite multiple treatment attempts including thalidomide, simvastatin and hemostatic factors. Only after initiation of propranolol, which has already been successfully used in three children with giant cerebral cavernoma, the occurrence of new CCM with hemorrhages was completely stopped already at dose of 30 mg daily – now for a period of 26 months and without any other medications.


      This case suggests a protective role for propranolol in preventing the occurrence of new cerebral cavernoma with hemorrhages in adults with multiple CCM.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Batra S.
        • Lin D.
        • Recinos P.F.
        • Zhang J.
        • Rigamonti D.
        Cavernous malformations: natural history, diagnosis and treatment.
        Nat. Rev. Neurol. 2009; 5: 659-670
        • Labauge P.
        • Denier C.
        • Bergametti F.
        • Tournier-Lasserve E.
        Genetics of cavernous angiomas.
        Lancet Neurol. 2007; 6: 237-244
        • Schneble H.M.
        • Soumare A.
        • Herve D.
        • Bresson D.
        • Guichard J.P.
        • Riant F.
        • Tournier-Lasserve E.
        • Tzourio C.
        • Chabriat H.
        • Stapf C.
        Antithrombotic therapy and bleeding risk in a prospective cohort study of patients with cerebral cavernous malformations.
        Stroke. 2012; 43: 3196-3199
        • Leaute-Labreze C.
        • Dumas D.R.
        • Hubiche T.
        • Boralevi F.
        • Thambo J.B.
        • Taieb A.
        Propranolol for severe hemangiomas of infancy.
        N. Engl. J. Med. 2008; 358: 2649-2651
        • Moschovi M.
        • Alexiou G.A.
        • Stefanaki K.
        • Tourkantoni N.
        • Prodromou N.
        Propranolol treatment for a giant infantile brain cavernoma.
        J. Child Neurol. 2010; 25: 653-655
        • Berti I.
        • Marchetti F.
        • Skabar A.
        • Zennaro F.
        • Zanon D.
        • Ventura A.
        Propranolol for cerebral cavernous angiomatosis: a magic bullet.
        Clin. Pediatr. (Phila.). 2014; 53: 189-190
        • Cavalheiro S.
        • Campos H.G.
        • Silva da Costa M.D.
        A case of giant fetal intracranial capillary hemangioma cured with propranolol.
        J. Neurosurg. Pediatr. 2016; 29: 1-6
        • Zabramski J.M.
        • Kalani M.Y.
        • Filippidis A.S.
        • Spetzler R.F.
        Propranolol treatment of cavernous malformations with symptomatic hemorrhage.
        World Neurosurg. 2015; (epub, Nov 11)
        • Eisa-Beygi S.
        • Wen X.Y.
        • Macdonald R.L.
        A call for rigorous study of statins in resolution of cerebral cavernous malformation pathology.
        Stroke. 2014; 45: 1859-1861